

# Marc van de Vijver

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2579229/marc-van-de-vijver-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29  
papers

7,511  
citations

23  
h-index

29  
g-index

29  
ext. papers

8,291  
ext. citations

11  
avg, IF

4.67  
L-index

#	Paper	IF	Citations
29	Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 106, 958-967	4	10
28	A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. <i>Cancer Research</i> , <b>2019</b> , 79, 4315-4323	4.23	4
27	Dilemmas for the pathologist in the oncologic assessment of pancreatoduodenectomy specimens : An overview of different grossing approaches and the relevance of the histopathological characteristics in the oncologic assessment of pancreatoduodenectomy specimens. <i>Virchows Archiv Für Pathologische Anatomie Und Physiological And Experimental Clinical Medicine</i> , <b>2018</b> , 473, 533-543	5.1	25
26	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. <i>Nature</i> , <b>2017</b> , 543, 714-718	50.4	157
25	Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 631-8	4	77
24	Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. <i>Science</i> , <b>2014</b> , 345, 1251343	33.3	250
23	HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. <i>Modern Pathology</i> , <b>2014</b> , 27, 4-18	9.8	191
22	Prevalence of serrated polyps and association with synchronous advanced neoplasia in screening colonoscopy. <i>Endoscopy</i> , <b>2014</b> , 46, 219-24	3.4	85
21	The landscape of cancer genes and mutational processes in breast cancer. <i>Nature</i> , <b>2012</b> , 486, 400-4	50.4	1264
20	HER2 testing in gastric cancer: a practical approach. <i>Modern Pathology</i> , <b>2012</b> , 25, 637-50	9.8	386
19	Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. <i>Nature Genetics</i> , <b>2011</b> , 43, 621-9	36.3	902
18	HER-2 amplification is highly homogenous in gastric cancer. <i>Human Pathology</i> , <b>2010</b> , 41, 304-5; author reply 305-6	3.7	37
17	Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 119, 119-26	4.4	125
16	Radiation-associated breast tumors display a distinct gene expression profile. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 76, 540-7	4	49
15	Emerging technologies for assessing HER2 amplification. <i>American Journal of Clinical Pathology</i> , <b>2009</b> , 132, 539-48	1.9	123
14	Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 115, 101-13	4.4	64
13	Estrogen receptor phenotypes defined by gene expression profiling. <i>Cancer Treatment and Research</i> , <b>2009</b> , 147, 1-18	3.5	

12	A conditional mouse model for malignant mesothelioma. <i>Cancer Cell</i> , <b>2008</b> , 13, 261-71	24.3	104
11	Clinical Genomics in Oncology <b>2008</b> , 209-229		
10	Lung metastasis genes couple breast tumor size and metastatic spread. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 6740-5	11.5	305
9	American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 118-45	2.2	2616
8	Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. <i>Breast Cancer Research</i> , <b>2007</b> , 9, R68	8.3	51
7	Current and future pathological examination in breast cancer. <i>European Journal of Cancer, Supplement</i> , <b>2005</b> , 3, 121-130	1.6	
6	A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. <i>Cancer Research</i> , <b>2005</b> , 65, 4059-66	10.1	212
5	Gene-expression profiling and the future of adjuvant therapy. <i>Oncologist</i> , <b>2005</b> , 10 Suppl 2, 30-4	5.7	53
4	Determination of stromal signatures in breast carcinoma. <i>PLoS Biology</i> , <b>2005</b> , 3, e187	9.7	161
3	Improving patient care through molecular diagnostics. <i>Seminars in Oncology</i> , <b>2004</b> , 31, 14-20	5.5	21
2	Current perspectives on HER2 testing: a review of national testing guidelines. <i>Modern Pathology</i> , <b>2003</b> , 16, 173-82	9.8	207
1	Emerging technologies for HER2 testing. <i>Oncology</i> , <b>2002</b> , 63 Suppl 1, 33-8	3.6	32